Erector Spinae Block With Ropivacaine and Dexmedetomidine on Opioid Consumption After Lumar Spine Surgeries

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-15

Study Completion Date

2023-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to investigate the role of 0.5 micrograms/kg of dexmedetomidine with 0.2 % ropivacaine in erector spinae block in reducing opioid consumption for patients undergoing lumbar spine surgeries. This study will help in understanding the role of adding dexmdetomidine to ropivacaine in erector spinae block in reducing opioid consumption after lumbar spine surgeries

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adding Dexmedetomidine to Bupivacaine for Bilateral Erector Spinae Block

NCT06231979

Erector Spinae Block Lumbar Fusion Surgeries Dexmedetomidine

NOT_YET_RECRUITING PHASE4

Dexmedetomidine and Morphine as Adjuvants to US Guided Erector Spinae Plane Blocks in Elective Thoracic Surgeries

NCT05843344

Pain, Postoperative Pain, Acute Pain, Chronic +3 more

UNKNOWN NA

Dexmedetomidine Combined With Bupivacaine for Erector Spinae Plane Block

NCT05590234

Posterior Lumbosacral Spine Fixation Surgeries

COMPLETED PHASE1/PHASE2

Erector Spinae Block Using a Dexmedetomidine Versus Magnesium Sulfate as an Adjuvant to Bupivacaine

NCT05694897

Postoperative Analgesia

COMPLETED NA

Erector Spinae Plane Block Versus Conventional Analgesia in Complex Spine Surgery

NCT04156581

Opioid Use Pain, Postoperative

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A number of adjuvants have been used with local anesthetics including dexamethasone, nalbuphine and dexmedetomidine etc with the aim of improving quality and duration of peripheral nerve blocks. Dexmedetomidine is a potent alpha-2 agonist which can prolong the duration of regional anesthesia block when used in combination with local anesthetics. Although, there is no consensus on the dose of dexmedetomidine for peripheral nerve block considering the fact that it can lower heart rate and blood pressure intraoperatively. Investigators therefore, planned this randomised controlled trial to investigate the role of 0.5 micrograms/kg of dexmedetomidine with 0.2 % ropivacaine in erector spinae block for patients undergoing lumbar spine surgeries.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

2 groups, one with block and other with no block

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Procedure will be done after patient will undergo GA for surgery. Medications will be prepared by anesthetist not involved in the study. The nurse/doctor who will assess the outcome will not know the group allocation

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ESPB group

this group will receive ESPB using ropivacaine and dexmedetomidine

Group Type EXPERIMENTAL

ESPB (regional Block)

Intervention Type OTHER

ESPB is regional block in which we will use 0.2 % ropivacaine and dexmedetomidine

ropivacaine and dexmedetomidine

Intervention Type DRUG

0.2 % ropivacaine and dexmedetomidine

Control group

this group will not receive any block

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ESPB (regional Block)

ESPB is regional block in which we will use 0.2 % ropivacaine and dexmedetomidine

Intervention Type OTHER

ropivacaine and dexmedetomidine

0.2 % ropivacaine and dexmedetomidine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged between 18 and 70 years, scheduled to undergo lumbar spine surgeries with an ASA score of 1 to 3 will be included in the study

Exclusion Criteria

* Patients who refused enrollment or later requested removal for the study, those who are unable to give informed consent and patients with either contraindications for regional anesthesia, known allergy to local anesthetics or dexmedetomidine, bleeding diathesis, use of anticoagulants or corticosteroids, inability to operate patient controlled analgesia (PCA) system, psychiatric disorders or use of psychiatric medications will not be included in the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No